Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

European Medicines Agency

Dec 19, 2017 8:00 AM - Dec 19, 2017 3:00 PM

30 Churchill Place, Canary Wharf, London, E14 5EU, United Kingdom

EMA Information Day on Risk Management Planning – Implementation of GVP V and RMP Template Rev 2 Guidance

REGISTER EARLY! This Information Day is aimed at providing MAHs and MAAs with practical advice on RMP drafting using the principles of risk assessment and management included in GVP V Rev 2.

CHALLENGES IN IMPLEMENTING THE UPDATED RMP GUIDANCE – STAKEHOLDERS’ PERSPECTIVE

Session Chair(s)

Jordi  Llinares Garcia, MS

Jordi Llinares Garcia, MS

Head of Research and Innovation

European Medicines Agency, Netherlands

Zeljana   Margan Koletic

Zeljana Margan Koletic

HALMED, Croatia (Hrvatska)

PRAC and Industry’s perspectives on the implementation of the updated guidance will be complemented by additional EMA guidance and advice on procedural aspects of RMP submission.

Speaker(s)

Sabine  Straus, MD, PhD, MSc

PRAC perspective on RMP guidance

Sabine Straus, MD, PhD, MSc

Medicines Evaluation Board (MEB), Netherlands

PRAC Chair, Staff Member

Emil Andrei  Cochino, MD, MHS

Procedural aspects of RMP update – EMA advice on procedural topics raised by stakeholders

Emil Andrei Cochino, MD, MHS

European Medicines Agency, Netherlands

Scientific Senior Specialist (Risk Management)

Nuria  Semis-Costa, MSc

Procedural aspects of RMP update – EMA advice on procedural topics raised by stakeholders

Nuria Semis-Costa, MSc

European Medicines Agency, Netherlands

Scientific Specialist (Risk Management)

Valerie E. Simmons, MD, FFPM

RMP guidance implementation – Industry perspective

Valerie E. Simmons, MD, FFPM

Eli Lilly and Company Ltd, United Kingdom

Senior Medical Fellow, Global Patient Safety

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.